Pirfenidone Clinical Guide: Dose Escalation, Taking with Food, and Side Effect Management

　　1.Overview and Mechanism

　　Pirfenidone(brand name:Esbriet)is an oral antifibrotic agent indicated for idiopathic pulmonary fibrosis(IPF).It works by inhibiting TGF-βmediated fibroblast proliferation and collagen deposition,reducing pro-inflammatory cytokine release,thereby slowing the decline in lung function.

　　2.Dose Escalation and Maintenance

　　To minimize initial side effects,pirfenidone requires gradual dose escalation:

　　Weeks 1–2:200 mg(1 tablet)three times daily(total 600 mg/day).

　　Weeks 3–4:400 mg(2 tablets)three times daily(total 1200 mg/day).

　　Weeks 5–6:600 mg(3 tablets)three times daily(total 1800 mg/day).

　　From Week 7 onward:800 mg(4 tablets)three times daily(total 2400 mg/day)as maintenance.

　　Dose adjustments must be made under medical supervision.

　　3.Taking with Food

　　Pirfenidone should be taken with meals,ideally during or immediately after breakfast,lunch,and dinner.Food buffers gastric irritation and slows gastric emptying,significantly reducing nausea,diarrhea,and dyspepsia.Taking it on an empty stomach increases the risk and severity of GI side effects and may compromise adherence.

　　4.Missed Dose Management

　　If a dose is missed:

　　If more than 4 hours remain before the next scheduled dose:Take the missed dose immediately,then resume the regular schedule.

　　If less than 4 hours remain:Skip the missed dose and take the next dose at the usual time.Never take a double dose​to compensate.

　　Setting medication reminders is recommended to avoid missed doses.

　　5.Common Side Effects and Mitigation

　　Photosensitivity rash(30–50%):Erythema and itching on sun-exposed skin.Mitigation:strict sun protection(SPF≥50 sunscreen,wide-brimmed hats,protective clothing),avoid prolonged sun exposure between 10:00 and 16:00.

　　Gastrointestinal reactions(30–40%):Nausea,diarrhea,anorexia.Mitigation:always take with food,escalate dose slowly,avoid high-fat and spicy foods.

　　Liver enzyme abnormalities(2–5%):Elevated ALT/AST.Mitigation:monitor liver function before treatment and at months 1,3,6,then every 6 months;reduce or interrupt dose if elevated.

　　Others:Dizziness,fatigue,weight loss(10–20%),usually mild to moderate and manageable with dose adjustment.Severe photosensitivity or hepatotoxicity is rare but requires immediate medical attention.

　　6.Conclusion

　　Pirfenidone is a key antifibrotic therapy for IPF.Adhering to dose escalation,taking with food,sun protection,and regular liver monitoring are essential for optimizing benefit and safety.